Metropolis Healthcare (METROPOLIS) delivered strong Q3FY26 performance with Group Revenue up 26% YoY to ₹406 Cr, and PAT soaring 63% YoY to ₹51 Cr.

Organic revenue also grew 15% YoY to ₹371 Cr, pushing EBITDA margins to 25.0% (+280 bps). Growth was fueled by preventive wellness (TruHealth) and specialty testing, reflected in 14% patient volume and 13% test volume growth.

The company's Metropolis 3.0 strategy drives market share expansion in specialized diagnostics, leverages digital tools for efficiency, and expands into adjacencies like genomics.

Recent highlights include launching a Centre of Genomics with Illumina, adding 300+ new NGS tests, and integrating AI diagnostics.

Management aims for mid-teen revenue CAGR through FY26, targeting pre-COVID margins and fastest growth among national chains, alongside network expansion to ~750 towns.